Digital Health Solutions for Alpha-Gal Syndrome: A Scoping Review of Telemedicine Evidence and Applications

Abstract

Alpha-gal syndrome (AGS) is an emerging allergy initiated by tick bites that leads to delayed IgE-mediated hypersensitivity reactions to galactose-α-1,3-galactose (α-gal), a carbohydrate present in mammalian tissues. Symptoms are highly variable and include urticaria, gastrointestinal distress, and life-threatening anaphylaxis. Diagnosis relies on patient history and serological testing for α-gal-specific IgE antibodies. This scoping review, following PRISMA methodology, evaluates telemedicine for clinical management of AGS. The syndrome’s characteristic delayed response pattern poses distinct challenges for standard allergy management protocols. Telehealth presents compelling solutions by enabling structured follow-up, remote data collection, and patient support, which is especially critical given that AGS is concentrated in geographic areas with limited specialist access and low provider familiarity. A case study of successful AGS desensitization using remotely monitored oral immunotherapy provides proof-of-principle for telemedicine’s transformative potential. Integrating telehealth is a strategic approach to improve diagnosis, facilitate long-term management, and strengthen surveillance for this increasingly prevalent condition.

Introduction

Alpha-gal syndrome (AGS) comprises an array of symptoms corresponding to immune-mediated hypersensitivity reactions to galactose-α-1,3-galactose (α-gal), a carbohydrate found in nonprimate mammals including cow, goat, pig, and sheep.¹ AGS deviates substantially from conventional food allergies in several critical respects. In contrast to traditional food allergies, where allergic symptoms typically develop within minutes of consumption, allergic symptoms in AGS often begin more than two hours after consuming mammalian products.¹ Additionally, the IgE antibodies form against a carbohydrate rather than an antigenic protein, and sensitization is affiliated with ectoparasite exposure, particularly Amblyomma americanum (lone star tick) in the United States.¹

Missouri represents a critical epicenter for AGS, ranking among states with the highest prevalence of suspected cases per population.² Recent comprehensive analysis of 343 AGS patients diagnosed at the University of Missouri revealed distinct clinical patterns that underscore the syndrome’s impact on the state’s healthcare system.³ This cohort demonstrated marked rural predominance, particularly among pediatric patients, with 64.8% of children residing in rural counties compared to 40.8% of adults. Pediatric presentations differed substantially from adults, showing significantly higher rates of gastrointestinal symptoms (35.2% vs. 19.2% for nausea/vomiting) and lower rates of anaphylaxis (2.3% vs. 6.7%), challenging conventional understanding of AGS manifestations across age groups.

The geographic distribution patterns observed in Missouri align with broader national data showing prevalence rates of alpha-gal sensitization approaching 50% within the “three corner” region of Missouri, Arkansas, and Oklahoma.⁴ This concentration coincides with areas of lone star tick populations and elevated ehrlichiosis infection rates. Risk factors for AGS development include documented tick bites, residence in areas with deer populations (woodland, larger properties with vegetation), and outdoor activities.⁵ Importantly, a strong association exists between alphagal specific IgE antibodies and tick exposure, with 98% of case patients demonstrating positive serology.⁶

Individual and familial risk factors further complicate the clinical landscape. Patients with AGS are more likely to have atopy, evidenced by other food allergies, childhood allergies, heightened cutaneous reactions to insect bites, and elevated IgE antibodies to various allergens.⁶ They are also eight times as likely to have family members with AGS, suggesting genetic predisposition or shared environmental exposures. However, these familial effects could be attributed to lifestyle factors such as peridomestic exposure, outdoor activities, or enhanced AGS knowledge among affected families.⁶

The healthcare delivery challenges posed by AGS are particularly acute in Missouri’s mixed urban-rural geography. The rural predominance of pediatric cases, combined with lower median alpha-gal IgE titers in this population, creates diagnostic complexity in areas with limited specialist access.³ While allergy specialists diagnosed 75% of pediatric and 67.5% of adult cases in the Missouri cohort, primary care providers managed 13.6% and 21.2% respectively, highlighting the need for cross-specialty education given that non-allergists more frequently documented the gastrointestinal symptoms that dominate pediatric presentations.

Current management emphasizes mammalian meat and product avoidance. Even though IgE levels decrease over time, significant studies documenting AGS resolution through avoidance are lacking. For individuals interested in ending dietary restrictions, desensitization through oral immunotherapy (OIT) presents an option, though traditional protocols require considerable in-person monitoring due to safety concerns.⁷

The integration of telemedicine into allergy and immunology practice has gained considerable momentum, with support from the American Academy of Allergy, Asthma and Immunology (AAAAI) and the American College of Allergy, Asthma and Immunology (ACAAI).⁸ These organizations anticipate that telemedicine will enhance health outcomes, expand care access, refine resource usage, decrease costs, and elevate collaboration between patients and physicians.^8,9 For conditions like food allergy and atopic dermatitis, telemedicine proves suitable since physical examination is often nonobligatory.¹⁰

Individuals with AGS serve as ideal candidates for telemedicine applications, particularly given the delayed nature of reactions and the rural concentration of cases in states like Missouri. A recent case report demonstrated successful AGS desensitization using remote monitoring, where a 63-year-old woman living considerable distance from her medical practice completed OIT with telemedicine oversight.⁷ This proof-of-principle case suggests broader potential for digital health solutions to address the geographic and logistical barriers that complicate AGS management in rural populations.

Given Missouri’s prominent role in AGS epidemiology and the demonstrated feasibility of telemedicine approaches, a comprehensive evaluation of digital health applications for this condition is warranted to inform clinical practice and healthcare policy in the region.

Methods

This scoping review was designed and reported in line with the Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA) framework, providing structured guidance for conducting reviews. This ensured transparency and consistency of the process and methodological rigor.

Eligibility Criteria

Studies were included in this review if the following criteria were met: 1) focused on patients diagnosed with or suspected of having AGS; 2) involved the use of digital health solutions such as telemedicine, telehealth, or any form of remote monitoring or consultation as part of the diagnosis, management, or treatment; and 3) were published in English language. All study designs, including original research, case reports, case series, commentaries, and narrative reviews were considered for inclusion to ensure a comprehensive scope of the available literature on this emerging topic.

Studies were excluded if the focus was on a single specific tick-borne disease other than AGS (e.g., Lyme disease), as findings from such research may not be generalizable to AGS. However, studies on telehealth for tick-borne diseases in general, or those addressing food allergies more broadly, were included if their findings could reasonably apply to AGS management.

Information Sources and Search Strategy

A comprehensive literature search was performed in Medline Ovid, Web of Science and Google Scholar from their inception to August 2025. The search strategy was developed in consultation with two coauthors (MB and BC) and was built upon two main concepts: 1) Alpha-Gal Syndrome and 2) telemedicine. For the first concept (AGS), a wide range of subject headings and keywords were used, including: “galactose-alpha-1,3-galactose,” “red meat allergy,” “alpha-gal syndrome,” “alpha-gal allergy,” “mammalian meat allergy,” and related terms. This concept also included broader terms like “food hypersensitivity,” as well as terms related to “tick-borne diseases” and “tick bites,” which were then combined with AGS-specific terms to capture all relevant articles. For the second concept (telemedicine), keywords included: “telemedicine,” “telehealth,” “remote consultation,” “virtual health,” “digital health,” and “remote monitoring.”

These two concepts were combined using the ‘AND’ Boolean operator to identify articles at the intersection of both topics. The search strategy was adapted for Google Scholar using key search strings such as (“alpha-gal syndrome” OR “red meat allergy”) AND (telemedicine OR telehealth OR “remote monitoring”). Additionally, the reference lists of all included articles were manually screened to identify any further relevant studies. The detailed search query for Medline Ovid is documented in Appendix A.

Study Selection

The study selection process was conducted by three reviewers (AEZSA, MB, BC) independently. First, the titles and abstracts of all retrieved articles were screened against the predefined eligibility criteria. Articles that clearly did not meet the criteria were excluded. Next, the full texts of all potentially relevant articles were retrieved and assessed for eligibility by all reviewers. Any discrepancies or disagreements between the reviewers at either the screening or full-text review stage were resolved through discussion and consensus.

Data Extraction

A standardized data charting form was developed to extract relevant information from the studies included. Three reviewers independently extracted the data. The following information was collected from each study: author(s), title, year of publication, journal name, Digital Object Identifier (DOI), specific details of the telemedicine intervention, key findings related to the intervention, and the study’s relevance to AGS. The extracted data was then used to generate a narrative summary of the existing literature.

Results

Study Selection

A total of 19 records were identified through database searching, with an additional 11 records identified through other sources. After removing duplicates, 29 records remained for screening. Of these, 22 records were screened and seven were excluded. The full text of 22 articles was assessed for eligibility, and one article was excluded for other reasons. Finally, 21 studies were included in the context of this scoping review (Figure 1).

Figure 1.

PRISMA flow diagram of study selection process for the scoping review.

Direct AGS Telehealth Evidence

The Wu et al. case study addresses a significant challenge that is particularly acute for Missouri’s rural patient population.⁷ The authors describe the treatment of a 63-year-old female with an initial anti-alphagal IgE level of 10.9 kUA/L who experienced severe anaphylactic reactions after eating meat. The patient’s demanding work schedule and significant distance from the clinic made traditional, lengthy desensitization appointments impractical. To overcome this, Wu et al. implemented a novel at-home oral immunotherapy protocol using a 14-step dose escalation of cooked, 100% beef hot dogs.⁷ Telehealth protocol allowed direct communication access to physicians, and the patient was equipped with epinephrine autoinjectors.

They concluded that oral desensitization for AGS can be feasible and effectively conducted using a combination of a novel desensitization protocol and telemedicine. This case demonstrates relevance to Missouri healthcare delivery, where many AGS patients reside in rural counties with limited specialist access.³ The geographic barriers overcome in this case, such as significant distance from clinic and work schedule conflicts with prolonged observations, mirror challenges faced by Missouri patients seeking AGS care.

Wu et al.’s case study prompted a commentary from Richard L. Wasserman, who points out that the unique, delayed nature of AGS reactions may mean this specific protocol is not directly generalizable to other food allergies that cause more immediate reactions.^7,11 He questions the precise role of telemedicine, wondering if its purpose was for direct observation (challenging given the uncertain timing of reactions) or for patient reassurance and data collection. For other food allergies, remote observation is more straightforward, as reactions typically occur within 30 minutes, allowing a provider to advise immediately.¹¹

The author raises significant safety concerns regarding patient adherence.¹¹ Without the regular, in person visits that serve to reinforce protocols and review sick day rules, Wasserman worries that patients might be tempted to alter their treatment plan, such as by accelerating doses, thereby increasing their risk of reaction.¹¹

Further contextualizing these findings, Jutel et al. connects both AGS and telemedicine to the broader One Health framework, which integrates human, animal, and environmental health. The paper highlights AGS as a key One Health-related research topic.¹² This positions the syndrome as an exemplary condition arising from the interaction between humans and animal vectors. Concurrently, the paper advocates telemedicine as a tool to create a more sustainable and accessible healthcare system. While not a clinical study, this study provides a conceptual framework that endorses both the study of AGS and the use of telemedicine as integral components of a modern, holistic approach to allergy and immunology.¹²

Telehealth Applications from Broader Allergy Literature

Out of extracted papers, 17 did not directly address AGS. However, the findings related to telehealth in general allergy, food allergy, and immunology may be relevant and applicable to optimizing the care pathway for AGS patients. These studies provide a strong basis for incorporating virtual care into both the diagnosis and long-term management of AGS.

Applications to AGS Diagnosis

Although definitive AGS diagnosis often requires specific laboratory testing, telehealth applications can significantly refine the pre-diagnostic and initial consultation phases. Approaches from five papers demonstrated applicability to the diagnostic workflow.

Two studies demonstrated that new patient allergy consultations can be effectively conducted via synchronous telehealth, a model that could improve access to specialists for initial AGS evaluation.^13,14 An electronic multidimensional health assessment questionnaire (eMDHAQ), provides a viable method for patients to remotely document their comprehensive history, including crucial details like tick exposure and reaction timing, for a clinician’s review.¹⁵ In addition, an online tool for near-real-time reporting of allergic reactions would be invaluable for capturing the specific details of delayed anaphylaxis that are characteristic of AGS.¹⁶ Finally, Martin et al. discussed using telehealth data and web searches for syndromic surveillance of tick-borne diseases, a method that could be applied to AGS to gain earlier public health awareness and clinical recognition.¹⁷

Applications to AGS Management

Managing AGS primarily centers on strict dietary avoidance and readiness for accidental exposure. Telehealth strategies outlined in the literature provide broad support across these critical areas. Strategies from 17 of the papers are applicable to the long-term management of AGS.

The efficacy of telenutrition for monitoring diet adherence can be generalizable to supporting AGS patients.¹⁸ Mobile health (mHealth) tools offer further support; a smartphone-based Personal Allergy Assistant that helps patients track intake and scan food barcodes could be adapted to warning against mammalian ingredients, aligning with the broader potential of mHealth in disease management.¹⁸ Given the risk of severe reactions, mobile health technology for anaphylaxis emergency preparedness could provide crucial decision support.¹⁹

Furthermore, the general benefits of telemedicine for routine allergy care are widely applicable to AGS management. Studies confirmed high patient satisfaction and effectiveness, showing that telehealth can increase access to specialists and be more time- and cost-effective.^8,14,20,21 These established advantages of virtual platforms underscore their value in providing continuous, long-term support for individuals living with AGS.

Discussion

The distinctive clinical characteristics of AGS present challenges for disease management, positioning telemedicine as a strategically important tool. The delayed onset of AGS reactions renders standard allergy protocols, designed for immediate responses, less applicable to this condition.¹¹ This temporal gap raises questions about the role of telemedicine: its function shifts from real-time observation of acute reactions to a model focused on patient reassurance, structured follow-up, and systematic data collection. The clinical urgency for such support is underscored by the findings of Binder et al., who demonstrated that 75% of AGS patients meet the criteria for anaphylaxis, with a high prevalence of severe systemic and gastrointestinal symptoms.²²

The Wu et al. case provides a possible roadmap for addressing Missouri’s documented geographic disparities in AGS care, where rural patients face both elevated disease prevalence and diminished specialist access.⁷ There is a concentrated geographic burden of suspected AGS in the southern, midwestern, and mid-Atlantic United States, a pattern mirroring regional tick habitats.³ Provider awareness presents an additional challenge. Thompson et al. reported that among surveyed providers, 42% had never heard of AGS, and 35% expressed limited confidence in their ability to diagnose or manage patients with AGS.² Telehealth can address these gaps by expanding specialist access, facilitating education on delayed reaction management, supporting remote follow-up for complex interventions, and strengthening public health surveillance and case reporting. Although most of the reviewed literature does not focus specifically on AGS, it consistently points to areas where telemedicine is well suited to make an impact. Telemedicine should therefore be viewed not merely as a convenience, but as a strategic approach to enhance diagnosis, sustain long-term management, and strengthen surveillance for this emerging health challenge.

For Missouri healthcare systems, the Wu et al. protocol offers a scalable model that leverages the state’s academic medical centers as telemedicine hubs while serving rural populations.⁷ The delayed reaction inherent to AGS makes this condition uniquely suited to remote management, distinguishing it from other food allergies and positioning Missouri to lead in AGS telemedicine implementation. Alpha-gal titers are known to decline over time in the absence of repeated tick exposures.²³ Thus, interpretation of the effectiveness of the Wu et al. protocol for desensitization is limited by the six months of time the patient was under study. Future controlled studies are needed to demonstrate its scalability.

The findings from the broader allergy literature reinforce the potential and provide a clear roadmap. To address the diagnostic challenges of delayed reactions, telehealth platforms can be adapted to include tools like the electronic multidimensional health assessment questionnaire (eMDHAQ), allowing for detailed, remote documentation of patient history. This can be coupled with online tools for near real-time reporting of allergic reactions helping to bridge the temporal gap between consumption and symptom onset. For ongoing management, studies confirm the efficacy of telenutrition in monitoring dietary adherence, while mHealth tools like a smartphone-based Personal Allergy Assistant could be modified to help patients avoid mammalian-derived ingredients. Given the high risk of severe reactions, mobile technology for anaphylaxis emergency preparedness is also directly applicable. Importantly, multiple studies confirm that synchronous tele-allergy services for both new and follow-up visits are effective, well-received by patients, and improve access to specialists directly answering the need created by the geographic and knowledge gaps in AGS care.

Appendix A. Search Strategy and Results from MEDLINE (Ovid)

Table 1.

Alpha-gal Syndrome and Telemedicine Search Results in MEDLINE (Ovid)

#	Searches	Results
1	galactose-alpha-1,3-galactose.mp.	396
2	red meat allergy.mp. or red meat allergy/	266
3	“galactosyl-(1–3)-galactose”.mp.	509
4	alpha-galactosyl epitope.mp.	263
5	GLA protein, human.mp.	228
6	alpha-galactosidase II.mp.	11
7	“O-alpha-galactopyranosyl(1–4)-O-beta-galactopyranosyl(1–4)-2-acetamido-2-deoxy-alpha-glucopyranose”.mp.	1
8	alpha-gal syndrome.mp.	266
9	alpha-gal allergy.mp.	66
10	“galactose-alpha-1,3-galactose allergy”.mp.	6
11	“galactose-alpha-1,3-galactose allergy”.mp.	6
12	mammalian meat allergy.mp.	53
13	red meat sensitization.mp.	0
14	“alpha-gal sensitization”.mp.	38
15	food hypersensitivity/ or food allergy.mp.	25,437
16	tick bites/ or tick bite.mp. or tick-borne diseases/ or tick-borne disease.mp.	7,098
17	1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11 or 12 or 13 or 14 or 15	26,568
18	16 and 17	174
19	telemedicine/ or telehealth.mp.	54,927
20	remote consultation.mp.	6,795
21	virtual health.mp.	1,396
22	teledermatology.mp. or teledermatology/	1,540
23	(teleallergy or tele-allergy).mp.	7
24	“Project ECHO”.mp.	391
25	“Extension for Community Healthcare Outcomes”.mp.	340
26	19 or 20 or 21 or 22 or 23 or 24 or 25	61,832
27	17 and 26	19
28	18 and 26	0